H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

Shares of Korro Bio and Wave Life Sciences sank Monday after an analyst argued the former is the better way to play the ...

Fintel reports that on October 21, 2024, Raymond James initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Strong Buy ...

Korro Bio (KRRO) announced a submission to the Bellberry HREC for a Phase 1/2 clinical study of KRRO-110 for AATD. A Clinical Advisory Board, ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports.

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...

RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...

Raymond James initiated coverage of Korro Bio (KRRO) with a Strong Buy rating and $153 price target The firm believes RNA editing will provide better therapeutic modality than DNA editing and/or ...

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...